{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:21:11Z","timestamp":1787779271666,"version":"build-2784847793"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world persistence with antiobesity pharmacotherapy is suboptimal: only 32% to 50% of patients persist with glucagon-like peptide-1 receptor agonists at 12 months, and fewer than 15% reach the 2.4 mg\/week target dose. Digital platforms may support engagement, but their role remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate whether baseline engagement with a structured digital assessment platform (Aviitam\n                      <jats:sup\/>\n                      ) predicts 48-week persistence and mediates weight-loss outcomes in adults with severe obesity initiating semaglutide 2.4 mg\/week and to identify clinical and behavioral predictors of pharmacological response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective 48-week single-center observational cohort, all consecutive adults (\u226518 y) with a BMI \u226540 kg\/m\u00b2 initiating semaglutide 2.4 mg\/week through the French early-access program were enrolled. Baseline engagement with the Aviitam\n                      <jats:sup\/>\n                      digital assessment platform was operationalized as a 3-level ordinal variable (never used, partial use, and full completion of validated questionnaires), reflecting the patient\u2019s responses to a nonenforced preclinical request. The primary outcome was 48-week persistence; secondary outcomes were full-dose attainment, percentage weight change, and dose-response. Adjusted logistic and linear regressions estimated the engagement-persistence and engagement-weight-loss associations. A Baron-Kenny mediation analysis with bootstrap CIs decomposed the engagement-weight-loss association. Missing 48-week weights were imputed using multiple imputation (m=20) as a sensitivity analysis. Among persistent participants who completed all 7 baseline questionnaires (n=91), behavioral-scale associations with weight change were analyzed using Benjamini-Hochberg false-discovery-rate correction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 191 participants (mean age 51.7, SD 6.8 y; 61\/191, 31.9% male; mean BMI 45.7, SD 6.8 kg\/m\u00b2), 37 (19.4%) had never used the platform, 32 (16.8%) used it partially, and 122 (63.9%) fully completed the questionnaires. At 48 weeks, 142 (74.3%) remained on semaglutide, and 124 (87.3%) of them reached the 2.4 mg\/week dose. Persistence followed a monotonic gradient across engagement levels (22\/37, 59.5%; 23\/32, 71.9%; 97\/122, 79.5%;\n                      <jats:italic>P<\/jats:italic>\n                      =.02), and each engagement increment was associated with higher odds of persistence (adjusted odds ratio 1.62, 95% CI 1.05\u20102.50;\n                      <jats:italic>P<\/jats:italic>\n                      =.03), unchanged under multiple imputation. Mean weight loss was 11.8% (SD 8.4%) in the full cohort and 14.6% (SD 7.3%) among persistent participants, with a steep dose-response (mean 3.9%, SD 5.8% in discontinuers to mean 15.3%, SD 7.2% at 2.4 mg\/week;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;.001). Mediation analysis showed 48-week persistence mediated approximately 69% of the engagement\u2013weight-loss association; the direct effect was nonsignificant. The Intuitive Eating Scale-2 was the only behavioral predictor surviving false-discovery-rate correction (\n                      <jats:italic>q<\/jats:italic>\n                      =0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline engagement with a structured digital assessment platform predicts 48-week semaglutide persistence in a graded manner; low-engagement patients can be identified at initiation and supported with targeted strategies to maintain persistence and achieve full-dose titration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/80119","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:53:31Z","timestamp":1787777611000},"page":"e80119-e80119","source":"Crossref","is-referenced-by-count":0,"title":["Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study"],"prefix":"10.2196","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-917X","authenticated-orcid":false,"given":"Sarah","family":"Tournayre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5830-8962","authenticated-orcid":false,"given":"Jean-baptiste","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9184-0393","authenticated-orcid":false,"given":"Jean","family":"Anitcheou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1524-8279","authenticated-orcid":false,"given":"Marion","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6839-4531","authenticated-orcid":false,"given":"Catherine","family":"Boegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-4859","authenticated-orcid":false,"given":"Abdulkader","family":"Jalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7448-4410","authenticated-orcid":false,"given":"Dominique","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1406-7835","authenticated-orcid":false,"given":"Camille","family":"Le Rouzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1840","authenticated-orcid":false,"given":"Vincent","family":"Attalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9259-5845","authenticated-orcid":false,"given":"Justine","family":"Myzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5290-5253","authenticated-orcid":false,"given":"Youadigue","family":"Kemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-8222","authenticated-orcid":false,"given":"Ariane","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-132X","authenticated-orcid":false,"given":"Antoine","family":"Avignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1","unstructured":"World obesity atlas 2023. World Obesity. URL: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023 [Accessed 12-05-2026]"},{"issue":"3","key":"R2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","journal-title":"N Engl J Med"},{"issue":"1","key":"R3","doi-asserted-by":"publisher","DOI":"10.2196\/53576","article-title":"Current implementation of digital health in chronic disease management: scoping review","volume":"26","author":"Pong","journal-title":"J Med Internet Res"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","journal-title":"N Engl J Med"},{"issue":"10278","key":"R5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","journal-title":"Lancet"},{"issue":"10","key":"R6","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration-a Danish cohort study","volume":"47","author":"Ladebo","journal-title":"Diabetes Care"},{"issue":"5","key":"R7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","journal-title":"JAMA Netw Open"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","journal-title":"JAMA Netw Open"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"R10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.23952","article-title":"Early- and later-stage persistence with antiobesity medications: a retrospective cohort study","volume":"32","author":"Gasoyan","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"R11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/oby.70222","article-title":"Corrigendum to \u201cNutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society\u201d","volume":"34","journal-title":"Obesity (Silver Spring)"},{"issue":"9596","key":"R12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","journal-title":"Lancet"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2016.05.001","article-title":"Validation of a French-Canadian adaptation of the Intuitive Eating Scale-2 for the adult population","volume":"105","author":"Carbonneau","journal-title":"Appetite"},{"issue":"5","key":"R14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.encep.2016.02.009","article-title":"Validation of the French version of the Binge Eating Scale: examination of its factor structure, internal consistency and construct validity in a non-clinical and a clinical population [Article in French]","volume":"42","author":"Brunault","journal-title":"Encephale"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-014-0354-0","article-title":"A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees","volume":"14","author":"Boc\u00e9r\u00e9an","journal-title":"BMC Psychiatry"},{"issue":"2","key":"R16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2478\/S13382-012-0024-8","article-title":"Psychometric properties of the French versions of the Perceived Stress Scale","volume":"25","author":"Lesage","journal-title":"Int J Occup Med Environ Health"},{"issue":"2","key":"R17","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1155\/2010\/438676","article-title":"The Epworth Sleepiness Scale: self-administration versus administration by the physician, and validation of a French version","volume":"17","author":"Kaminska","journal-title":"Can Respir J"},{"key":"R18","unstructured":"Morin CM . Insomnia: Psychological Assessment and Management. Guilford Press; 1993. ISBN: 9780898622102"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","DOI":"10.52057\/erj.v3i1.33","article-title":"The construct validity of the Ricci and Gagnon questionnaire to assess the physical activity level: a prospective study","volume":"3","author":"Reychler","journal-title":"Eur Rehabil J"},{"issue":"6","key":"R20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1037\/\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","journal-title":"J Pers Soc Psychol"},{"issue":"3","key":"R21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3758\/brm.40.3.879","article-title":"Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models","volume":"40","author":"Preacher","journal-title":"Behav Res Methods"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Rubin DB . Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons; 1987. ISBN: 9780470316696","DOI":"10.1002\/9780470316696"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","journal-title":"J Stat Softw"},{"key":"R24","volume":"12","author":"Pedregosa","journal-title":"J Mach Learn Res"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"24","key":"R26","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa1306187","article-title":"CPAP, weight loss, or both for obstructive sleep apnea","volume":"370","author":"Chirinos","journal-title":"N Engl J Med"},{"issue":"5","key":"R27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5665\/sleep.2618","article-title":"Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes","volume":"36","author":"Kuna","journal-title":"Sleep"},{"issue":"11","key":"R28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2337\/diacare.15.11.1455","article-title":"Family history of diabetes in relation to different types of obesity and change of obesity during 12-yr period. Results from prospective population study of women in G\u00f6teborg, Sweden","volume":"15","author":"Lapidus","journal-title":"Diabetes Care"},{"issue":"5","key":"R29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/joim.12289","article-title":"Family history of type 2 diabetes increases the risk of both obesity and its complications: is type 2 diabetes a disease of inappropriate lipid storage?","volume":"277","author":"Cederberg","journal-title":"J Intern Med"},{"issue":"2","key":"R30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/oby.20027","article-title":"Adaptive thermogenesis with weight loss in humans","volume":"21","author":"M\u00fcller","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"R31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/eat.23509","article-title":"Intuitive eating and its psychological correlates: a meta-analysis","volume":"54","author":"Linardon","journal-title":"Int J Eat Disord"},{"issue":"1","key":"R32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/a0030893","article-title":"The Intuitive Eating Scale-2: item refinement and psychometric evaluation with college women and men","volume":"60","author":"Tylka","journal-title":"J Couns Psychol"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:53:32Z","timestamp":1787777612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2026\/1\/e80119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/80119","relation":{},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"v28i3e80119"}}